Leber’s Hereditary Optic Neuropathy
- 1.7k Downloads
Leber’s hereditary optic neuropathy (LHON) is a maternally inherited blinding disease with variable penetrance. Three primary mitochondrial DNA mutations, affecting the respiratory complex I, are necessary but not sufficient to cause blindness. Reduced efficiency of ATP synthesis and increased oxidative stress are believed to sensitize the retinal ganglion cells to apoptosis. Different therapeutic strategies are considered to counteract this pathogenic mechanism. However, potential treatments for the visual loss are complicated by the fact that patients are unlikely to benefit after optic atrophy occurs. There is no proven therapy to prevent or reverse the optic neuropathy in LHON. Results from a recent trial with idebenone hold promise to limit neurodegeneration and improve final outcome, promoting recovery of visual acuity. Other therapeutic options are under scrutiny, including gene therapy, agents increasing mitochondrial biogenesis, and anti-apoptotic drugs.
KeywordsOptical Coherence Tomography Retinal Nerve Fiber Layer Optic Neuropathy Mitochondrial Permeability Transition Pore Mitochondrial Permeability Transition Pore
No potential conflicts of interest relevant to this article were reported.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance••Of major importance
- 30.Mahidol University: A randomized, double-blind, placebo-controlled trial of curcumin in Leber’s hereditary optic neuropathy (LHON). In: ClinicalTrials.gov [Internet}. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/study/NCT00528151.
- 36.Eng JG, Aggarwal D, Sadun AA: Idebenone treatment in patients with Leber hereditary optic neuropathy [abstract]. Invest Ophthalmol Vis Sci 2009, 50(Suppl):1440.Google Scholar
- 37.Chinnery P, et al.: Results of a 6-months randomized, placebo-controlled trial (RHODOS) with idebenone (Catena®) in Leber’s Hereditary Optic Neuropathy (LHON) [poster WIP-3]. Presented at the 135th Annual Meeting of the American Neurological Association. San Francisco, CA; September 14, 2010.Google Scholar
- 40.••Perales-Clemente E, Fernández-Silva P, Acín-Pérez R, et al.: Allotopic expression of mitochondrial-encoded genes in mammals: achieved goal, undemonstrated mechanism or impossible task? Nucleic Acids Res 2010 Sep 7 (Epub ahead of print).This careful study demonstrates how apparent complementation of the mitochondrial dysfunction by using the approach of allotopic expression may be due to selection of mtDNA mutation revertants.Google Scholar
- 41.Figueroa-Martínez F, Vázquez-Acevedo M, Cortés-Hernández P, et al.: What limits the allotopic expression of nucleus-encoded mitochondrial genes? The case of the chimeric Cox3 and Atp6 genes. Mitochondrion 2010 Sep 18 (Epub ahead of print).Google Scholar
- 44.••Giordano C, Montopoli M, Perli E, et al.: Estrogens ameliorate mitochondrial dysfunction in Leber’s hereditary optic neuropathy. Brain 2010, in press. This study demonstrated the role of estrogens in compensating for mitochondrial dysfunction in LHON and explains the reduced penetrance in females.Google Scholar